File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Diode laser transscleral cyclophotocoagulation as primary surgical treatment for medically uncontrolled chronic angle closure glaucoma: Long-term clinical outcomes

TitleDiode laser transscleral cyclophotocoagulation as primary surgical treatment for medically uncontrolled chronic angle closure glaucoma: Long-term clinical outcomes
Authors
Issue Date2005
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.glaucomajournal.com
Citation
Journal Of Glaucoma, 2005, v. 14 n. 2, p. 114-119 How to Cite?
AbstractPurpose: To evaluate the long-term efficacy and safety of diode laser transscleral cyclophotocoagulation as primary surgical treatment of medically uncontrolled chronic angle closure glaucoma. Patients and Methods: Thirteen eyes of 13 Chinese patients with medically uncontrolled chronic angle closure glaucoma were treated with diode laser transscleral cyclophotocoagulation between February 2000 and May 2001, and followed up for over 18 months. Post-treatment anti-glaucoma medications were adjusted according to intraocular pressure. If intraocular pressure remained above 21 mm Hg despite medications for more than 4 weeks after cyclophotocoagulation, the procedure was repeated. Results: Mean follow-up ± SD was 26.5 ± 4.2 months. Two eyes required repeat cyclophotocoagulation at 6 weeks. Rate of relative success, defined as maintaining an intraocular pressure of 21 mm Hg or below with or without medications, was 92.3% (12 of 13 eyes). Rate of absolute success, defined as maintaining an intraocular pressure of 21 mm Hg or below without medications, was 0% (0 of 13 eyes). Mean ± SD intraocular pressure was reduced from 36.4 ± 12.6 mm Hg pre-operatively, to 18.7 ± 12.2 mm Hg at final follow-up (P = 0.003, paired t test). The mean ± SD number of intraocular pressure-lowering eye drops was reduced from 2.0 ± 0.8 pre-operatively, to the lowest point of 0.5 ± 0.8 at 12 months, and then gradually increased to 2.1 ± 0.9 at final follow-up. The visual acuity improved after treatment in 2 of 13 eyes (15.4%), remained unchanged in 6 of 13 eyes (46.2%) and deteriorated in 5 of 13 eyes (38.5%). No major complications were encountered. Conclusion: Diode laser cyclophotocoagulation appeared to be an effective and safe primary surgical treatment of medically uncontrolled chronic angle closure glaucoma, with intraocular pressure-lowering effect persisting for up to two years. Copyright © 2005 by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/176414
ISSN
2015 Impact Factor: 2.102
2015 SCImago Journal Rankings: 1.477
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLai, JSMen_US
dc.contributor.authorTham, CCYen_US
dc.contributor.authorChan, JCHen_US
dc.contributor.authorLam, DSCen_US
dc.date.accessioned2012-11-26T09:11:07Z-
dc.date.available2012-11-26T09:11:07Z-
dc.date.issued2005en_US
dc.identifier.citationJournal Of Glaucoma, 2005, v. 14 n. 2, p. 114-119en_US
dc.identifier.issn1057-0829en_US
dc.identifier.urihttp://hdl.handle.net/10722/176414-
dc.description.abstractPurpose: To evaluate the long-term efficacy and safety of diode laser transscleral cyclophotocoagulation as primary surgical treatment of medically uncontrolled chronic angle closure glaucoma. Patients and Methods: Thirteen eyes of 13 Chinese patients with medically uncontrolled chronic angle closure glaucoma were treated with diode laser transscleral cyclophotocoagulation between February 2000 and May 2001, and followed up for over 18 months. Post-treatment anti-glaucoma medications were adjusted according to intraocular pressure. If intraocular pressure remained above 21 mm Hg despite medications for more than 4 weeks after cyclophotocoagulation, the procedure was repeated. Results: Mean follow-up ± SD was 26.5 ± 4.2 months. Two eyes required repeat cyclophotocoagulation at 6 weeks. Rate of relative success, defined as maintaining an intraocular pressure of 21 mm Hg or below with or without medications, was 92.3% (12 of 13 eyes). Rate of absolute success, defined as maintaining an intraocular pressure of 21 mm Hg or below without medications, was 0% (0 of 13 eyes). Mean ± SD intraocular pressure was reduced from 36.4 ± 12.6 mm Hg pre-operatively, to 18.7 ± 12.2 mm Hg at final follow-up (P = 0.003, paired t test). The mean ± SD number of intraocular pressure-lowering eye drops was reduced from 2.0 ± 0.8 pre-operatively, to the lowest point of 0.5 ± 0.8 at 12 months, and then gradually increased to 2.1 ± 0.9 at final follow-up. The visual acuity improved after treatment in 2 of 13 eyes (15.4%), remained unchanged in 6 of 13 eyes (46.2%) and deteriorated in 5 of 13 eyes (38.5%). No major complications were encountered. Conclusion: Diode laser cyclophotocoagulation appeared to be an effective and safe primary surgical treatment of medically uncontrolled chronic angle closure glaucoma, with intraocular pressure-lowering effect persisting for up to two years. Copyright © 2005 by Lippincott Williams & Wilkins.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.glaucomajournal.comen_US
dc.relation.ispartofJournal of Glaucomaen_US
dc.subject.meshAgeden_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshCiliary Body - Surgeryen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGlaucoma, Angle-Closure - Surgeryen_US
dc.subject.meshHumansen_US
dc.subject.meshIntraocular Pressureen_US
dc.subject.meshLaser Coagulation - Methodsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshSafetyen_US
dc.subject.meshSclera - Surgeryen_US
dc.subject.meshTreatment Outcomeen_US
dc.subject.meshVisual Acuityen_US
dc.titleDiode laser transscleral cyclophotocoagulation as primary surgical treatment for medically uncontrolled chronic angle closure glaucoma: Long-term clinical outcomesen_US
dc.typeArticleen_US
dc.identifier.emailLai, JSM: laism@hku.hken_US
dc.identifier.authorityLai, JSM=rp00295en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/01.ijg.0000151890.41239.c5en_US
dc.identifier.pmid15741811-
dc.identifier.scopuseid_2-s2.0-15244359388en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-15244359388&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume14en_US
dc.identifier.issue2en_US
dc.identifier.spage114en_US
dc.identifier.epage119en_US
dc.identifier.isiWOS:000227730900005-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLai, JSM=7401939748en_US
dc.identifier.scopusauthoridTham, CCY=7006081241en_US
dc.identifier.scopusauthoridChan, JCH=26024354100en_US
dc.identifier.scopusauthoridLam, DSC=35500200200en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats